Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity

Molecular Cancer Research

Volumn 7, Issue 4, 2009, Pages 536-548

  Kasiappan, Ravi ^a   Shih, Hung Ju ^a,b   Chu, Kang Lin ^a   Chen, Wei Ti ^a   Liu, Hui Ping ^c   Huang, Shiu Feng ^a   Chik, On Choy ^a   Shu, Chung Li ^a   Din, Richard ^d   Chu, Jan Show ^e   Hsu, Hsin Ling ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCARBOXYLATE TRANSPORTER 1; PROTEIN P53; RAS PROTEIN; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; HRAS PROTEIN, HUMAN; MCTS1 PROTEIN, HUMAN; MUTAGENIC AGENT; ONCOPROTEIN; PROTEIN P21; RAF PROTEIN; TP53 PROTEIN, HUMAN;

ANEUPLOIDY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOKINESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; DRUG POTENTIATION; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE TRANSLOCATION; GENETICS; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CYTOGENETIC ANALYSIS; DRUG SYNERGISM; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MUTAGENS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65549131527     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0422     Document Type: Article

References (35)

1. Bozcuk H, Uslu G, Pe̊tereli E, et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 2001;68:239-248
2. Borel F, Lohez OD, Lacroix FB, Margolis RL. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci U S A 2002;99:9819-9824
3. Salisbury JL, D'Assoro AB, Lingle WL. Centrosome amplification and the origin of chromosomal instability in breast cancer. J Mammary Gland Biol Neoplasia 2004;9:275-283 (Pubitemid 39545744)
4. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19. (Pubitemid 41506955)
5. van de Wetering CI, Horne MC, Knudson CM. Chromosomal instability and supernumerary centrosomes represent precursor defects in a mouse model of T-cell lymphoma. Cancer Res 2007;67:8081-8088 (Pubitemid 47395142)
6. Brunet S, Vernos I. Chromosome motors on the move. From motion to spindle checkpoint activity. EMBO Rep 2001;2:669-673
7. Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006;111:974-984 (Pubitemid 44137383)
8. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60-65 (Pubitemid 46109297)
9. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 2001;1:109-117 (Pubitemid 33741886)
10. Draviam VM, Xie S, Sorger PK. Chromosome segregation and genomic stability. Curr Opin Genet Dev 2004;14:120-125 (Pubitemid 38520138)
11. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12. (Pubitemid 40991810)
12. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-1747 (Pubitemid 26102826)
13. Sphyris N, Harrison DJ. p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene 2005;24:2184-2194 (Pubitemid 40516585)
14. Yun C, Cho H, Kim SJ, et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004;2:159-169
15. Fukasawa K, Vande Woude GF. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 1997;17:506-518 (Pubitemid 26425640)
16. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ. MAPK mediates RAS-induced chromosome instability. J Biol Chem 1999;274:38083-38090 (Pubitemid 30026878)
17. Saavedra HI, Knauf JA, Shirokawa JM, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000;19:3948-3954
18. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac- MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005;280:14675-14683 (Pubitemid 40562814)
19. Lee KW, Kim MS, Kang NJ, et al. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-κB: an implication for invasive phenotype in rat liver epithelial cells. Int J Cancer 2006; 119:1767-1775
20. 2 DNA damage and mitotic spindle checkpoints. J Biol Chem 2006;281:3800-3809
21. Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 2003; 102:297-302. (Pubitemid 36759668)
22. Hsu HL, Shi B, Gartenhaus RB. The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells. Oncogene 2005;24:4956-4964 (Pubitemid 41129099)
23. Hsu HL, Choy CO, Kasiappan R, et al. MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage. DNA Repair 2007;6:1319-1332
24. Prosniak M, Dierov J, Okami K, et al. A novel candidate oncogene, MCT-1, is involved in cell cycle progression. Cancer Res 1998;58:4233-4237
25. Nandi S, Reinert LS, Hachem A, et al. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage. Oncogene 2007;26:2283-2289
26. Fleischer TC, Weaver CM, McAfee KJ, Jennings JL, Link AJ. Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev 2006;20:1294-1307 (Pubitemid 43727590)
27. Reinert LS, Shi B, Nandi S, et al. MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles. Cancer Res 2006;66:8994-9001.
28. Levenson AS, Thurn KE, Simons LA, et al. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res 2005;65:10651-10656
29. Wakisaka N, Pagano JS. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res 2003;3:2133-2138 (Pubitemid 36897173)
30. Giancotti FG. Targeting integrin β4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci 2007;28:506-511 (Pubitemid 47488503)
31. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell 2004;6:471-483 (Pubitemid 39469983)
32. Kanies CL, Smith JJ, Kis C, et al. Oncogenic Ras and transforming growth factor-β synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. Mol Cancer Res 2008;6:1124-1136
33. Halaschek-Wiener J, Wacheck V, Kloog Y, Jansen B. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal 2004; 16:1319-1327 (Pubitemid 39165460)
34. Mazan-Mamczarz K, Hagner PR, Corl S, et al. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008;27:6151-6163
35. Jänicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008;15:959-976, Review.